Great interview with CEO Gary Rabin on Seeking Alpha today.
Gary was saying they are talking with China about partnering, I hope not, China will screw ACTC. A partnership with anyone but China would be great.
Advanced Cell Technology (ACTC.OB) is
a biotechnology company focused on the development and commercialization of
human embryonic and adult stem cell technology in the field of regenerative
medicine. Their main focus revolves around macular degeneration, which is an
unmet medical need for the world worth well over $30 billion. ACTC has treated
nine patients between their three ongoing trials. All of the patients are
reported as doing remarkably well, and there have been no safety issues
whatsoever. The most exciting thing to report is that the success rate is
running at 100% for those treated. Obviously there is much more to the story,
and if interested, then one should view the ACTC website and presentations for a
greater understanding
That up the share price just a little to closed at 0.0813 on 2.7 million shares. The three month avg. is 5.2 million shares.
Geron down 4 cents at $1.72 on 764,592 shares. The three month avg. volume is 712,632 shares. It's just a waiting game, good result in Dec 2012 we move up to $3 to $5, poor results 3 to 5 cents.
I love AAPL up $ 15.73 to close $610.75. It's going higher
Good luck in this rigged casino,
Tuesday, July 31, 2012
Geron beats by 1 cent misses on rev
I listened to the call, trials are moving along, 3 Phase 2 trials results Dec 2012, 1 Phase 2 trial [breast cancer] 1st quarter 2013 and 2 Phase 2 [with GRN1005] in the 2nd quarter of 2013. No good news. Chip stated no Phase 3 trials without a partner. Geron has money for the Phase 2 trials only. If results are good Geron will find a partner if not they are done as a company. No deal on the stem cell property.
Good luck in this rigged casino,
Good luck in this rigged casino,
Monday, July 30, 2012
Geron earnings call July 31 at 9AM EST
Very disappointed, no follow through on Geron. It went down 8 cents to close at $1.76 on 775,131 shares. The three month avg. volume is 706,581 shares. I was very close to selling a few covered but chickened out. Now lets hope Chip has some thing good to say.
ACTC closed at 0.0808 should be moving up a little with the trials moving foreword.
AAPL you got to love it up $9.87 to close at $595.03. on 13.5 million shares. The three month avg. volume is 15.6 million shares.
Good luck in this rigged casino,
ACTC closed at 0.0808 should be moving up a little with the trials moving foreword.
AAPL you got to love it up $9.87 to close at $595.03. on 13.5 million shares. The three month avg. volume is 15.6 million shares.
Good luck in this rigged casino,
ACTC treats 10th patient in Embryonic Stem Cell Trials
ACT Treats 10th Patient in Embryonic Stem Cell Trials for Macular Degeneration
Jul 30, 2012 08:30:01 (ET)
MARLBOROUGH, Mass., Jul 30, 2012 (BUSINESS WIRE) -- Advanced Cell Technology, Inc. ("ACT"; OTCBB: ACTC), a leader in the field of regenerative medicine, today announced treatment of the final patient in the first patient cohort in its Phase 1/2 clinical trial for Stargardt's macular dystrophy (SMD) using retinal pigment epithelial (RPE) cells derived from human embryonic stem cells (hESCs). The surgery was performed on Friday, July 27 at Moorfields Eye Hospital in London, the same site as the first two treatments, by a team of surgeons led by Professor James Bainbridge, consultant surgeon at Moorfields and Chair of Retinal Studies at University College London. The outpatient transplant surgery was performed successfully without any complications, and the patient is recovering uneventfully. This is the tenth patient overall to now be treated with the RPE cell therapy developed by the company.
"Our European trial is making very steady progress, having now completed enrollment of the first patient cohort," commented Gary Rabin, chairman and CEO. "We are very encouraged and look forward to receiving clearance to initiate the treatment of the second patient cohort in the coming weeks."
The Phase 1/2 trial is designed to determine the safety and tolerability of hESC-derived RPE cells following sub-retinal transplantation in patients with SMD at 12 months, the study's primary endpoint. It will involve a total of 12 patients, with cohorts of three patients each in an ascending dosage format. It is similar in design to the U.S. trial for SMD that was initiated in July 2011.
"This is a significant month for the company," continued Mr. Rabin. "One year ago we treated the first of our patients in our two U.S. clinical trials. The one-year follow-up for those initial patients indicates that the improvements in visual acuity we initially reported have in fact persisted now for a year. Indeed, we are consistently observing improvements in subjective and objective visual acuity for patients being treated at the various clinical centers involved in our trials. Again, these trials are still at very early stages, but these preliminary results indicate that we are on the right track."
The European Medicines Agency's (EMA) Committee for Orphan Medicinal Products (COMP) has officially designated ACT's human embryonic stem cell (hESC)-derived retinal pigment epithelial (RPE) cells as an orphan medicinal product for the treatment of SMD.
About Stargardt's Disease
Stargardt's disease or Stargardt's Macular Dystrophy is a genetic disease that causes progressive vision loss, usually starting in children between 10 to 20 years of age. Eventually, blindness results from photoreceptor loss associated with degeneration in the pigmented layer of the retina, called the retinal pigment epithelium, which is the site of damage that the company believes the hESC-derived RPE may be able to target for repair after administration.
About Advanced Cell Technology, Inc.
ACTC share price down a little. They are slowly moving foreword.
Geron up 3 cents, need more volume, will sell covered calls at $2
AAPL love the $10 move up.
Good luck in this rigged casino,
Jul 30, 2012 08:30:01 (ET)
MARLBOROUGH, Mass., Jul 30, 2012 (BUSINESS WIRE) -- Advanced Cell Technology, Inc. ("ACT"; OTCBB: ACTC), a leader in the field of regenerative medicine, today announced treatment of the final patient in the first patient cohort in its Phase 1/2 clinical trial for Stargardt's macular dystrophy (SMD) using retinal pigment epithelial (RPE) cells derived from human embryonic stem cells (hESCs). The surgery was performed on Friday, July 27 at Moorfields Eye Hospital in London, the same site as the first two treatments, by a team of surgeons led by Professor James Bainbridge, consultant surgeon at Moorfields and Chair of Retinal Studies at University College London. The outpatient transplant surgery was performed successfully without any complications, and the patient is recovering uneventfully. This is the tenth patient overall to now be treated with the RPE cell therapy developed by the company.
"Our European trial is making very steady progress, having now completed enrollment of the first patient cohort," commented Gary Rabin, chairman and CEO. "We are very encouraged and look forward to receiving clearance to initiate the treatment of the second patient cohort in the coming weeks."
The Phase 1/2 trial is designed to determine the safety and tolerability of hESC-derived RPE cells following sub-retinal transplantation in patients with SMD at 12 months, the study's primary endpoint. It will involve a total of 12 patients, with cohorts of three patients each in an ascending dosage format. It is similar in design to the U.S. trial for SMD that was initiated in July 2011.
"This is a significant month for the company," continued Mr. Rabin. "One year ago we treated the first of our patients in our two U.S. clinical trials. The one-year follow-up for those initial patients indicates that the improvements in visual acuity we initially reported have in fact persisted now for a year. Indeed, we are consistently observing improvements in subjective and objective visual acuity for patients being treated at the various clinical centers involved in our trials. Again, these trials are still at very early stages, but these preliminary results indicate that we are on the right track."
The European Medicines Agency's (EMA) Committee for Orphan Medicinal Products (COMP) has officially designated ACT's human embryonic stem cell (hESC)-derived retinal pigment epithelial (RPE) cells as an orphan medicinal product for the treatment of SMD.
About Stargardt's Disease
Stargardt's disease or Stargardt's Macular Dystrophy is a genetic disease that causes progressive vision loss, usually starting in children between 10 to 20 years of age. Eventually, blindness results from photoreceptor loss associated with degeneration in the pigmented layer of the retina, called the retinal pigment epithelium, which is the site of damage that the company believes the hESC-derived RPE may be able to target for repair after administration.
About Advanced Cell Technology, Inc.
ACTC share price down a little. They are slowly moving foreword.
Geron up 3 cents, need more volume, will sell covered calls at $2
AAPL love the $10 move up.
Good luck in this rigged casino,
Saturday, July 28, 2012
Geron up 8% good volume
Geron closed up 14 cent at $1.84 on 1,626,251 shares. The three month avg. volume is 688,470 shares. The earnings call is July 31 at 9AM. If we get more volume, say close to 2 million shares Monday with a price of $2.00+ then just maybe some thing good is coming. I will sell a few covered calls if we get a price over $2.00. Geron was in an article called "5 Biotech Stocks Poised for Breakout" at the Street. Stated that $2.22-$2.60 is the next level, if we get more volume and a breakout above $1.89.
ACTC was down just a little at 0.082 on 3.3 million shares. The three month avg. is 5.2 million shares.
AAPL was up $10.25 to close at $585.16 on 14.4 million shares. Still the best company out there.
Good luck in this rigged casino,
ACTC was down just a little at 0.082 on 3.3 million shares. The three month avg. is 5.2 million shares.
AAPL was up $10.25 to close at $585.16 on 14.4 million shares. Still the best company out there.
Good luck in this rigged casino,
Thursday, July 26, 2012
Geron earnings call July 31
Geron closed at 6 1/2 cents at $1.695 on 477,878 shares. The three month avg. is 688,470 shares. I will be listening July 31 at 9 AM EST. I don't think there will be any great news, hope I'm wrong.
ACTC up 4.62% to close at 0.0837 on 3.8 million shares. The three month avg. is 5.2 million shares. Waiting waiting waiting
AAPL down 9 cents at $574.88 on 14.5 million shares. The three month avg. is 15.7 million shares.
Good luck in this rigged casino.
ACTC up 4.62% to close at 0.0837 on 3.8 million shares. The three month avg. is 5.2 million shares. Waiting waiting waiting
AAPL down 9 cents at $574.88 on 14.5 million shares. The three month avg. is 15.7 million shares.
Good luck in this rigged casino.
ACTC issued patent for Human RPR Cells
ACT Issued Broad Patent for Human RPE Cells Derived From All Types of Pluripotent Stem Cells
New Australian Patent Covers Human RPE Cells Made From Range of Pluripotent Stem Cells, Including Both Embryonic Stem Cells and induced Pluripotent Stem (iPS) Cells
“We continue to make great progress with our patent estate covering RPE therapies,” said Gary Rabin, chairman and CEO of ACT. “Our ongoing success in securing broad patent protection around the world, including this newly-issued Australian patent, is a testament to our innovative chief scientific officer, Dr. Robert Lanza, and the rest of our scientific team.”
The efficient production of highly pure RPE cell preparations represents a critical step in the creation of renewable sources of transplantable cells that can be used to target degenerative diseases of the eye such as Stargardt’s Macular Dystrophy (SMD) and dry Age-related Macular Degeneration (dry AMD).
“Our current embryonic stem cell trials pave the way for other pluripotent stem cell therapies,” commented Dr. Lanza. “ACT’s cellular reprogramming technologies using iPS cells are in an advanced stage of development, and we hope to be in a position to move toward clinical translation in the not-too-distant future. Since iPS cells can be made from the patient’s own cells such as skin or blood cells they may allow us to expand our cell therapies beyond immune-privileged sites such as the eye without the risk of immune rejection.”
Mr. Rabin concluded, “We are aggressively pursuing patent protection for a variety of aspects of our programs. Our intellectual property strategy includes both vigilance in pursuing comprehensive coverage from our initial patent filings, such as this new Australian patent, and filing for protection around our scientific team’s various innovations. At the same time we are paying close attention to including within our patent coverage those ways others may wish to adapt our technology for commercial use, such as through the choice of stem cell source, or the use of solid supports or cell suspensions for delivery. Following this strategy, we are establishing both formidable barriers-to-entry for potential competitors, as well as strong potential licensing opportunities for others, translating into solid revenue generation possibilities for the company.
This is good news the stock price is up just a little, due to all the things that must happen for this company to survive. Need more good results from Phase 1/2, needs a partner, need a reverse split to get on the big broad. This company is a roll of the dice. I have 25,000 shares riding on that roll.
Good luck in this rigged casino,
The efficient production of highly pure RPE cell preparations represents a critical step in the creation of renewable sources of transplantable cells that can be used to target degenerative diseases of the eye such as Stargardt’s Macular Dystrophy (SMD) and dry Age-related Macular Degeneration (dry AMD).
“Our current embryonic stem cell trials pave the way for other pluripotent stem cell therapies,” commented Dr. Lanza. “ACT’s cellular reprogramming technologies using iPS cells are in an advanced stage of development, and we hope to be in a position to move toward clinical translation in the not-too-distant future. Since iPS cells can be made from the patient’s own cells such as skin or blood cells they may allow us to expand our cell therapies beyond immune-privileged sites such as the eye without the risk of immune rejection.”
Mr. Rabin concluded, “We are aggressively pursuing patent protection for a variety of aspects of our programs. Our intellectual property strategy includes both vigilance in pursuing comprehensive coverage from our initial patent filings, such as this new Australian patent, and filing for protection around our scientific team’s various innovations. At the same time we are paying close attention to including within our patent coverage those ways others may wish to adapt our technology for commercial use, such as through the choice of stem cell source, or the use of solid supports or cell suspensions for delivery. Following this strategy, we are establishing both formidable barriers-to-entry for potential competitors, as well as strong potential licensing opportunities for others, translating into solid revenue generation possibilities for the company.
This is good news the stock price is up just a little, due to all the things that must happen for this company to survive. Need more good results from Phase 1/2, needs a partner, need a reverse split to get on the big broad. This company is a roll of the dice. I have 25,000 shares riding on that roll.
Good luck in this rigged casino,
Wednesday, July 25, 2012
AAPL down $25.95, Geron up
The market didn't go down like I thought. The Feds said QE3 maybe coming soon, I think that saved the market for today. AAPL closed at $574.97, I added 4 more shares at around $575.50.
ACTC closed down just a little at 0.08 on only 2.5 million shares. The three month avg. is 5.3 million shares. It waiting for more good results, a partner, reverse split, added to big broad and more.
Geron was up 1 cent at $1.63 on only 287,228 shares. The three month avg.691,813 shares. Dec 2012 will be the big month, that will make or break this company. Four Phase 2 results will be reported.
Good luck in this rigged casino,
ACTC closed down just a little at 0.08 on only 2.5 million shares. The three month avg. is 5.3 million shares. It waiting for more good results, a partner, reverse split, added to big broad and more.
Geron was up 1 cent at $1.63 on only 287,228 shares. The three month avg.691,813 shares. Dec 2012 will be the big month, that will make or break this company. Four Phase 2 results will be reported.
Good luck in this rigged casino,
AAPL still the best company out there
Going to buy a call Jan 14 at $610. AAPL next 6 months should be better, buy 2014 should be over $650.
Market not down, that's a good sign, not the end of the world. Added more IBB at $129.75 Tuesday.
Good luck in this rigged casino,
Market not down, that's a good sign, not the end of the world. Added more IBB at $129.75 Tuesday.
Good luck in this rigged casino,
Tuesday, July 24, 2012
AAPL MISSES it's all over now baby blue
AAPL closed down $2.91 at $600.92. After hours the earnings came out and AAPL went down $33. I'm so glad I sold 10 shares at $610 a week ago. Now I will buy a few more shares Wednesday. Six months from now we should be back over $600.
The market will be down big time Wednesday and I will buy more IBB. People will always buy there drugs.
ACTC down a little at 0.0808 on only 1.9 million shares. The three month avg. volume is 5.3 million shares.
Geron closed down 2 cents at $1.62 on only 498,379 shares. The three month avg. volume is 702,130 shares.
Good luck in this rigged casino,
The market will be down big time Wednesday and I will buy more IBB. People will always buy there drugs.
ACTC down a little at 0.0808 on only 1.9 million shares. The three month avg. volume is 5.3 million shares.
Geron closed down 2 cents at $1.62 on only 498,379 shares. The three month avg. volume is 702,130 shares.
Good luck in this rigged casino,
In IBB 10 shares
People will always buy there drugs. Started with 10 shares IBB will work up to 100 shares and then sell a covered call. AAPL I was trying to get 100 shares but don't have the money now. It's still the best company out there. With earnings today AAPL was made and break the market. May add more AAPL if they miss.
Good luck in this rigged casino,
Good luck in this rigged casino,
Monday, July 23, 2012
AAPL earnings July 24
AAPL's earnings will make or break the market. If good the market goes higher if bad it's down we go. AAPL closed down just 47 cents at $603.83 on 17.4 million shares. The three month avg. volume is 16 million shares.
ACTC was down just a little at 0.0810 on 4.5 million shares. The three month avg. volume is 5.3 million shares. Waiting on more good results, a partner, a settlement with SEC, a reverse split, and listed on the big board.
Geron closed down 2 cents at $1.63 on 733,588 shares. The three month avg. volume is 702,130 shares. Geron earnings out on July 26.
I put a order in for a few shares of IBB, didn't get it. People will always buy there drugs.
Good luck in this rigged casino,
ACTC was down just a little at 0.0810 on 4.5 million shares. The three month avg. volume is 5.3 million shares. Waiting on more good results, a partner, a settlement with SEC, a reverse split, and listed on the big board.
Geron closed down 2 cents at $1.63 on 733,588 shares. The three month avg. volume is 702,130 shares. Geron earnings out on July 26.
I put a order in for a few shares of IBB, didn't get it. People will always buy there drugs.
Good luck in this rigged casino,
Friday, July 20, 2012
AAPL down ACTC up Geron same
AAPL was down $10.02 closed at $604.30 on 14.2 million shares. Three month avg. volume is 16.6 million shares. Earnings due out on July 24.
ACTC closed up a little at 0.080 on 3.6 million shares. The three month avg volume is 5.3 million shares. No news.
Geron closed flat at $1.65 on 612,175 shares. The three month avg. volume is 708,433 shares. No news till Dec 2012 on the 4 Phase 2 trials.
Good luck in this rigged casino,
ACTC closed up a little at 0.080 on 3.6 million shares. The three month avg volume is 5.3 million shares. No news.
Geron closed flat at $1.65 on 612,175 shares. The three month avg. volume is 708,433 shares. No news till Dec 2012 on the 4 Phase 2 trials.
Good luck in this rigged casino,
Thursday, July 19, 2012
Geron sys Patent Office rejected challenge to ViaCyte Patent
Geron Says Patent Office Rejected Challenge to ViaCyte Patent
Geron Corp. (GERN), the biotech company that last year abandoned its stem-cell clinical trials, said the U.S. Patent andTrademark Office turned away its challenge to a stem cell-related patent held by ViaCyte Inc., a San Diego-based competitor.According to a Geron regulatory filing, the patent office’s Board of Patent appeals and Interferences rejected arguments against claims in ViaCyte’s patent 7,510,876. The board also said that some of the claims in a Geron patent application were unpatentable.
The technology covered by the disputed application is part of its stem cell intellectual property portfolio the Menlo Park, California-based company is seeking to divest, Geron said.
In November 2011 Geron said in a statement that it would discontinue its clinical trials of its stem cell-related therapies to focus on oncology drugs.
Geron is the company that funded the University of Wisconsin research that first isolated stem cells from human embryos in 1998.
In July 2011 the company said it had won clearance from the U.S. Food and Drug Administration to test a therapy derived from those cells. Geron ended those trials because of research costs and regulatory complexities
Geron is trying to sell it's stem cell property, this will made it much harder and worth much less.
It's all going to come down to Dec 2012 the 4 Phase 2 trial results. If good I'm rich, if fair to poor I'll be working tell I drop dead.
Good luck in this rigged casino,
Wednesday, July 18, 2012
Geron loses hESC Patent case
Geron, now they can REALLY focus all their attention and resources on ONCOLOGY. Geron was down only 2 cents at $1.67, on only 420,866 shares. To me that means the hESC patent was not worth much.
ACTC was down a little at 0.08 on 7 million shares. The three month avg. volume is 5.3 million shares. If we break 7 cent I may add a few more shares.
AAPL closed down a little at $606.26 on 8.9 million shares. The three month avg. month is 17.2 million shares. The earnings are due July 24.
Good luck in this rigged casino,
|
Tuesday, July 17, 2012
Geron up on new patent
Geron received PATENT today. It sure seems to both be a precursor to use of Immetalstat as well as provide an independent metric to warn patients they may have cancer well before they even have symptoms. Who wouldn't take this test which I understand is non-intrusive?
IMHO this is better than what took Geron over $60/share in 2000.
IMHO
United States Patent 8,222,392
July 17, 2012
Kit for detection of telomerase reverse transcriptase nucleic acids
Abstract
The invention provides compositions and methods related to human telomerase reverse transcriptase (hTRT), the catalytic protein subunit of human telomerase. The polynucleotides and polypeptides of the invention are useful for diagnosis, prognosis and treatment of human diseases, for changing the proliferative capacity of cells and organisms, and for identification and screening of compounds and treatments useful for treatment of diseases such as cancers.
This is great news. I hope it can produce income soon.
Geron up 12 cents to closed at $1.69 on good volume of 1,433,755 shares. The three month avg. volume is 714,836 shares. Also STEM's good news should make Geron's stem cell property more valuable.
ACTC should have gone up on STEM's news, but it closed down a little at 0.0849 on 8.2 million shares. The three month avg. volume is 5.3 million shares.
AAPL up just a little at $606.94 on 10.5 million shares. The three month avg. is 17.5 million shares. The earnings date is July 26th.
Good luck in this rigged casino,
IMHO this is better than what took Geron over $60/share in 2000.
IMHO
United States Patent 8,222,392
July 17, 2012
Kit for detection of telomerase reverse transcriptase nucleic acids
Abstract
The invention provides compositions and methods related to human telomerase reverse transcriptase (hTRT), the catalytic protein subunit of human telomerase. The polynucleotides and polypeptides of the invention are useful for diagnosis, prognosis and treatment of human diseases, for changing the proliferative capacity of cells and organisms, and for identification and screening of compounds and treatments useful for treatment of diseases such as cancers.
This is great news. I hope it can produce income soon.
Geron up 12 cents to closed at $1.69 on good volume of 1,433,755 shares. The three month avg. volume is 714,836 shares. Also STEM's good news should make Geron's stem cell property more valuable.
ACTC should have gone up on STEM's news, but it closed down a little at 0.0849 on 8.2 million shares. The three month avg. volume is 5.3 million shares.
AAPL up just a little at $606.94 on 10.5 million shares. The three month avg. is 17.5 million shares. The earnings date is July 26th.
Good luck in this rigged casino,
Alzheimer in rats cured
Alzheimer in rats CURED.
StemCells announces its human neural stem cells restore memory in models of Alzheimer's Disease (STEM) 0.87 : The study results showed that transplanting the cells into a specific region of the brain, the hippocampus, statistically increased memory in two different animal models. Importantly, these results did not require reduction in beta amyloid or tau that accumulate in the brains of patients with AD and account for the pathological hallmarks of the disease.
It well be years [10-20] before its cures humans if ever. Remember Geron the stem cells cured paralysed rats and went to human trials and run out of money.
This all up the price today for Geron and ACTC.
Good luck in this rigged casino,
StemCells announces its human neural stem cells restore memory in models of Alzheimer's Disease (STEM) 0.87 : The study results showed that transplanting the cells into a specific region of the brain, the hippocampus, statistically increased memory in two different animal models. Importantly, these results did not require reduction in beta amyloid or tau that accumulate in the brains of patients with AD and account for the pathological hallmarks of the disease.
It well be years [10-20] before its cures humans if ever. Remember Geron the stem cells cured paralysed rats and went to human trials and run out of money.
This all up the price today for Geron and ACTC.
Good luck in this rigged casino,
Monday, July 16, 2012
ACTC up over 9
ACTC is up over 9 cent. Rumor is China may partner. If this is true we go a lot higher.
Good luck in this rigged casino,
Good luck in this rigged casino,
Friday, July 13, 2012
Good day for AAPL ACTC and Geron
All stocks up today, that doesn't happen everyday.
ACTC up a little again at 0.085 on 7.4 million shares. Waiting for a partner, a SEC lawsuit settlement and more positive results from Phase 1/2 trial results.
Geron up 5 cents at $1.58 on 349,025 shares. Dec 2012 is the judgement month with 4 Phase 2 trials results that will make or break them.
AAPL up $6.07 at $604.94 on 11 million shares. Earnings due July 16th this will be a market mover.
Good luck in this rigged casino,
ACTC up a little again at 0.085 on 7.4 million shares. Waiting for a partner, a SEC lawsuit settlement and more positive results from Phase 1/2 trial results.
Geron up 5 cents at $1.58 on 349,025 shares. Dec 2012 is the judgement month with 4 Phase 2 trials results that will make or break them.
AAPL up $6.07 at $604.94 on 11 million shares. Earnings due July 16th this will be a market mover.
Good luck in this rigged casino,
Thursday, July 12, 2012
Geron webcast more of the same
I listened to most of the webcast and read all the slides, nothing new. It's all coming down to Dec 2012 the 4 Phase 2 results if good to great Geron will be $5 to $10 a share, if bad to fair, 5 to 10 cents a share. The market moved Geron down to $1.53 on 624,098 shares. The three month avg. is 707,994 shares.
ACTC was up a little at 0.084, on great volume 18.3 million shares. The avg. three month is 5 million shares.
With ACTC's problem which are many, it all comes down to good results on the Phase 1/2 trials.
AAPL down again to $598.90 on 15.3 shares. The three month avg. is 18.4 million shares. If they miss earnings look out.
Good luck in this rigged casino,
ACTC was up a little at 0.084, on great volume 18.3 million shares. The avg. three month is 5 million shares.
With ACTC's problem which are many, it all comes down to good results on the Phase 1/2 trials.
AAPL down again to $598.90 on 15.3 shares. The three month avg. is 18.4 million shares. If they miss earnings look out.
Good luck in this rigged casino,
ACTC 1st Stargardt Patient Treated with higher dosage
| News | 0.0855 | 0.0026 |
ACT Announces First Stargardt Patient Treated With Higher Dosage of Embryonic Stem Cell-Derived Retinal Pigment Epithelial Cells
Jul 12, 2012 09:33:00 (ET)
MARLBOROUGH, Mass., Jul 12, 2012 (BUSINESS WIRE) -- Advanced Cell Technology, Inc. ("ACT"; OTCBB: ACTC), a leader in the field of regenerative medicine, today announced treatment of the fourth patient, the first in the second patient cohort, in its U.S. clinical trial for Stargardt's Macular Dystrophy (SMD). The surgery was performed on Wednesday, July 11 at Wills Eye Institute in Philadelphia, by a surgical team lead by Carl D. Regillo, MD, FACS, director of the Wills Eye Clinical Retina Research Unit, attending surgeon in the Wills Eye Retina Service at the Wills Eye Institute, and professor of ophthalmology at Thomas Jefferson University. In keeping with trial protocol, the patient was injected with 100,000 human embryonic stem cell-derived retinal pigment epithelial (RPE) cells, as compared with the 50,000 cell dose used in the three patients of the first cohort. The outpatient transplantation surgery was performed successfully and the patient is recovering uneventfully.
"It is very gratifying to have second cohort, higher-dosage patient treatment underway in our U.S. clinical trial for SMD," commented Gary Rabin, chairman and CEO of ACT. "We are also pleased to be working with Dr. Regillo and his team at Wills Eye Institute, a truly first-class institution that is ranked as one of the best ophthalmology hospitals in the country by U.S. News & World Report."
Initiated in July of last year, the Phase I/II trial is designed to determine the safety and tolerability of hESC-derived RPE cells following sub-retinal transplantation in patients with SMD at 12 months, the study's primary endpoint. It will involve a total of 12 patients, with cohorts of three patients each in an ascending dosage format. As part of its RPE clinical program, the company is concurrently conducting a clinical trial for dry age-related macular degeneration and second trial for SMD in the United Kingdom.
"Doubling the cell dosage marks an important milestone in our clinical programs," said Robert Lanza, MD, ACT's chief scientific officer. "We look forward to continued progress and safety findings in the coming months, in both our U.S. and European trials."
Further information about patient eligibility for ACT's SMD study and the concurrent studies in the U.S. and Europe (for dry age-related macular degeneration and SMD, respectively) are available at www.clinicaltrials.gov , with the following Identifiers: NCT01345006 (U.S. SMD), NCT01344993 (dry AMD), and NCT01469832 (E.U. SMD).
About Stargardt's Disease
Stargardt's disease or Stargardt's Macular Dystrophy is a genetic disease that causes progressive vision loss, usually starting in children between 10 to 20 years of age. Eventually, blindness results from photoreceptor loss associated with degeneration in the pigmented layer of the retina, called the retinal pigment epithelium, which is the site of damage that the company believes the hESC-derived RPE may be able to target for repair after administration
Good luck in this rigged casino,
ACTC up 22%
ACTC up 22% today and closed at 0.0829 on 15 million shares. The three month avg. volume is 5 million shares. If we can get 20%+ again Thur. then something good is up.
Geron up 3 cents at $1.57, webcast Thur at 11AM hoping for some good news and that's all it is hoping.
AAPL down and closed at $604.43.
Good luck in this rigged casino,
Geron up 3 cents at $1.57, webcast Thur at 11AM hoping for some good news and that's all it is hoping.
AAPL down and closed at $604.43.
Good luck in this rigged casino,
Wednesday, July 11, 2012
ACTC up big
ACTC was up 14% on big volume. Can't find reason why. Some body knows some thing?
Good luck in this rigged casino,
Good luck in this rigged casino,
Tuesday, July 10, 2012
Geron, ACTC and AAPL all down
AAPL down $5.68 at $608.21 on 18.3 million shares. The three month avg. volume is 18.8 million shares.
I sold 10 shares a few days ago at $610.12, but will hold the rest. Earnings if good we will go to $650 in a few weeks. If AAPL misses the whole market will go down, it will be all over but the shouting.
Geron closed down 11 cents at $1.54 on 826,194 shares. The three month avg. volume is 713,151 shares. I could not find any reason for the drop. Again with no good news we could free fall to $1. Need Chip to say and or do some thing positive.
ACTC was down just a little at 0.0675 on 7.8 million shares. The three month avg. volume is 4.8 million shares. Still think we will hit 7 cents.
Good luck in this rigged casino,
I sold 10 shares a few days ago at $610.12, but will hold the rest. Earnings if good we will go to $650 in a few weeks. If AAPL misses the whole market will go down, it will be all over but the shouting.
Geron closed down 11 cents at $1.54 on 826,194 shares. The three month avg. volume is 713,151 shares. I could not find any reason for the drop. Again with no good news we could free fall to $1. Need Chip to say and or do some thing positive.
ACTC was down just a little at 0.0675 on 7.8 million shares. The three month avg. volume is 4.8 million shares. Still think we will hit 7 cents.
Good luck in this rigged casino,
Monday, July 9, 2012
ACTC up on news
ACTC up 9.83% to 0.0693 on good volume 9.7 million shares. The three month avg. is 4.7 million shares. Read post earlier today on why ACTC is up. We should go a little higher.
AAPL up $8.01 closed at $613.89. On 13.5 million shares. I sold 10 shares at $610.12, we hold the rest. Earnings out July 16th.
Geron closed down a little at $1.65 on 709,887. The three month avg. volume is 730,868 shares. Looks like no good news on July 12 webcast.
Good luck in this rigged casino,
AAPL up $8.01 closed at $613.89. On 13.5 million shares. I sold 10 shares at $610.12, we hold the rest. Earnings out July 16th.
Geron closed down a little at $1.65 on 709,887. The three month avg. volume is 730,868 shares. Looks like no good news on July 12 webcast.
Good luck in this rigged casino,
ACTC given OK to increase RPE cells
Advanced Cell Technology, Inc. (“ACT”; OTCBB: ACTC), a leader in the field of regenerative medicine, announced today that the Data and Safety Monitoring Board (DSMB), an independent group of medical experts closely monitoring the company’s three ongoing clinical trials, has authorized the company to move forward with enrollment and treatment of additional patients in its clinical trial for dry age-related macular degeneration (dry AMD). ACT will proceed with patient screening and enrollment for the second cohort, who, in keeping with trial protocol, will be injected with 100,000 retinal pigment epithelial (RPE) cells derived from human embryonic stem cells (hESCs), as compared with the 50,000-cell dose used in the first cohort.
“DSMB authorization to move to the higher dosage of cells in our clinical trial for dry AMD represents a significant milestone for our clinical programs,” commented Gary Rabin, chairman and CEO of ACT. “Our RPE program is now advancing rapidly, as we are now screening at multiple ophthalmological centers for the fourth surgery in both our dry AMD trial and our U.S. SMD trial, with our E.U. SMD trial, which was initiated much later, not far behind.”
The trial is a prospective, open-label study, designed to determine the safety and tolerability of hESC-derived RPE cells following sub-retinal transplantation into patients with dry AMD at 12 months, the study’s primary endpoint. The three procedures comprising the first cohort of patients were all conducted at University of California at Los Angeles (UCLA), by Steven Schwartz, M.D., Ahmanson Professor of Ophthalmology at the David Geffen School of Medicine at UCLA and retina division chief at UCLA's Jules Stein Eye Institute. It was announced in May that Mass Eye and Ear is an additional site for the trial.
Mr. Rabin added, “Dry AMD represents one of the largest unmet ophthalmological needs in the world, with a potential market of $25 billion in the U.S. and Europe, alone, and this DSMB approval is a big step toward being able to potentially address that massive medical need.”
ACT is conducting a total of three clinical trials in the U.S. and Europe using hESC-derived RPE cells to treat forms of macular degeneration. Each trial will enroll a total of 12 patients, with cohorts of three patients each in an ascending dosage format. Treatment of the final patient of the first cohort in the company’s dry AMD trial was announced on April 20. On June 29, the second SMD patient enrolled in the Company’s E.U. clinical trial was treated at Moorfields Eye Hospital in London, U.K., and on April 24 the company announced DSMB approval to treat the second patient cohort in its U.S. SMD trial.
This is great news, hopefully it will move the share price higher.
Good luck in this rigged casino,
Friday, July 6, 2012
AAPL ACTC Geron all down
AAPL closed down $4.06 at $605.88 on 14.9 million shares. Three month avg. volume 730,198 shares. Earning due out July 24th.
Geron closed down 0.045 cents at $1.655 on 670,080 shares. The three month avg. volume is 730,198 shares. This was a few days ago. Geron Corporation (GERN) is showing weakness in today`s session as the company Is planning to sell up to $200M of any combination of shares, debt securities and warrants. The company would use the money for working capital and general corporate purposes, including R&D. Shares of GERN slid 6.82% to $1.64.
ACTC closed down a little at 0.0631 on 3.6 million shares. The three month avg. volume is 4.7 shares. Still waiting on SEC lawsuit settlement, a partner, reverse split and more good results from Phase 1/2 trial results.
Good luck in this rigged casino,
Geron closed down 0.045 cents at $1.655 on 670,080 shares. The three month avg. volume is 730,198 shares. This was a few days ago. Geron Corporation (GERN) is showing weakness in today`s session as the company Is planning to sell up to $200M of any combination of shares, debt securities and warrants. The company would use the money for working capital and general corporate purposes, including R&D. Shares of GERN slid 6.82% to $1.64.
ACTC closed down a little at 0.0631 on 3.6 million shares. The three month avg. volume is 4.7 shares. Still waiting on SEC lawsuit settlement, a partner, reverse split and more good results from Phase 1/2 trial results.
Good luck in this rigged casino,
Thursday, July 5, 2012
AAPL up big again
AAPL closed up $10.53 at $609.94 on 17 million shares. The three month avg. volume is 19.1 million shares. Still the best company out there.
Geron down 6 cent to close at $1.70 on 951,086 shares. The three month avg. volume is 724,616 shares. This company is one big gamble. They have the ok to sell 100,000,000 more shares, have can do it in any amount and at any time. They need a partner. They need to sell the stem cell business. They need good results from the 4 Phase 2 trials. If they have poor results from the four Phase 2 trials its all over.
ACTC was up a little at 0.0636 on 4.7 million shares. The 3 month avg. volume is 4.7 million shares. This company is a gamble to, the SEC lawsuit, need partner, need more good results from Phase 1/2 trials.
Good luck in this rigged casino,
Geron down 6 cent to close at $1.70 on 951,086 shares. The three month avg. volume is 724,616 shares. This company is one big gamble. They have the ok to sell 100,000,000 more shares, have can do it in any amount and at any time. They need a partner. They need to sell the stem cell business. They need good results from the 4 Phase 2 trials. If they have poor results from the four Phase 2 trials its all over.
ACTC was up a little at 0.0636 on 4.7 million shares. The 3 month avg. volume is 4.7 million shares. This company is a gamble to, the SEC lawsuit, need partner, need more good results from Phase 1/2 trials.
Good luck in this rigged casino,
Tuesday, July 3, 2012
Geron at JMP Securities Healthcare Conference July 12
Geron at JMP Securities Healthcare Conference Thursday July 12, 2012 11:30AM, will be webcast. Lets see if somebody knows something. The shares prices and volume should go up before conference if there is any good news coming. Geron closed down one cent at $1.76 on only 368,824 shares. The three month avg. volume is 728,849 shares.
ACTC closed up a little at 0.0625 on only 1.9 million shares. The three month avg. volume is 4.4 month shares. Just waiting for news.
AAPL closed up $6.89 at $599.41 on 8.6 million shares. The three month avg. volume is 19.5 million shares. Still the best company out there.
Good luck in this rigged casino,
ACTC closed up a little at 0.0625 on only 1.9 million shares. The three month avg. volume is 4.4 month shares. Just waiting for news.
AAPL closed up $6.89 at $599.41 on 8.6 million shares. The three month avg. volume is 19.5 million shares. Still the best company out there.
Good luck in this rigged casino,
Monday, July 2, 2012
Geron up ACTC up and AAPL up a good day
This is from the a Yahoo Message broad:
Cancer is #1 now, buy HESC's, with a partner, are still very much in GERN's future. The company is developing biopharmaceuticals for the treatment of cancer and chronic degenerative diseases.
Geron (GERN) is still a world leader in the development of human embryonic stem cell-based therapeutics, but for financial reasons, that is now taking a back seat.
Indefinite replicative capacity – indefinite proliferation to enable production of a limitless supply of cells for scalable manufacturing of products for clinical use.
Pluripotency – capacity to develop into most cell types for the potential treatment of a wide range of diseases and conditions.
HESCs serve as the starting material in the manufacture of specific functional therapeutic cell types. Cryopreserved, hESCs are thawed and expanded in their undifferentiated state to enable production of large multi-dose manufacturing lots. After the expansion stage, the undifferentiated hESCs are then treated with specific biologicals and growth factors to induce them to differentiate into specified functional cell types. Final product is cryopreserved for distribution and on-demand use at the point of care. Geron has developed new technologies and processes to support this product model.
Each therapeutic cell type derived from hESCs has multiple functional properties that cannot be mimicked by any single drug or conventional biologic, presenting a real opportunity to address significant unmet medical needs.
GRNOPC1 – Oligodendrocyte progenitors
GRNCM1 – Cardiomyocytes
GRNIC1 – Pancreatic islet cells
GRNCHND1 – Chondrocytes
GRNVAC2 – Dendritic cells.
Geron closed up 6 cent at $1.77 on just under 1 million shares. The three month avg. volume is 727,414 shares. We still need more volume but I think some thing good is coming.
ACTC closed up just a little at 0.0623 on 4.5 million shares. The three month avg. volume is 4.8 million shares. They are slowly moving forward with the Phase 1/2 trials with any more good results we should hit 12 cents. We would go high if we had the reverse split done, and the SEC lawsuit settled.
AAPL up $8.52 at $592.53 on 14.3 million shares. The three month avg. volume is 19.5 million shares.
AAPL is looking good, but I may sell a few shares before earnings, if we have more ran up.
Good luck in this rigged casino,
Cancer is #1 now, buy HESC's, with a partner, are still very much in GERN's future. The company is developing biopharmaceuticals for the treatment of cancer and chronic degenerative diseases.
Geron (GERN) is still a world leader in the development of human embryonic stem cell-based therapeutics, but for financial reasons, that is now taking a back seat.
Indefinite replicative capacity – indefinite proliferation to enable production of a limitless supply of cells for scalable manufacturing of products for clinical use.
Pluripotency – capacity to develop into most cell types for the potential treatment of a wide range of diseases and conditions.
HESCs serve as the starting material in the manufacture of specific functional therapeutic cell types. Cryopreserved, hESCs are thawed and expanded in their undifferentiated state to enable production of large multi-dose manufacturing lots. After the expansion stage, the undifferentiated hESCs are then treated with specific biologicals and growth factors to induce them to differentiate into specified functional cell types. Final product is cryopreserved for distribution and on-demand use at the point of care. Geron has developed new technologies and processes to support this product model.
Each therapeutic cell type derived from hESCs has multiple functional properties that cannot be mimicked by any single drug or conventional biologic, presenting a real opportunity to address significant unmet medical needs.
GRNOPC1 – Oligodendrocyte progenitors
GRNCM1 – Cardiomyocytes
GRNIC1 – Pancreatic islet cells
GRNCHND1 – Chondrocytes
GRNVAC2 – Dendritic cells.
Geron closed up 6 cent at $1.77 on just under 1 million shares. The three month avg. volume is 727,414 shares. We still need more volume but I think some thing good is coming.
ACTC closed up just a little at 0.0623 on 4.5 million shares. The three month avg. volume is 4.8 million shares. They are slowly moving forward with the Phase 1/2 trials with any more good results we should hit 12 cents. We would go high if we had the reverse split done, and the SEC lawsuit settled.
AAPL up $8.52 at $592.53 on 14.3 million shares. The three month avg. volume is 19.5 million shares.
AAPL is looking good, but I may sell a few shares before earnings, if we have more ran up.
Good luck in this rigged casino,
ACTC Announces 2nd patient with Stargardt's treated
MARLBOROUGH, Mass., Jul 02, 2012 (BUSINESS WIRE) -- Advanced Cell Technology, Inc. ("ACT"; OTCBB: ACTC), a leader in the field of regenerative medicine, today announced treatment of the second patient in its Phase 1/2 clinical trial for Stargardt's macular dystrophy (SMD) using retinal pigment epithelial (RPE) cells derived from human embryonic stem cells (hESCs). The surgery was performed on Friday, June 29 at Moorfields Eye Hospital in London, the same site as the first patient treatment in January, by a team of surgeons led by Professor James Bainbridge, consultant surgeon at Moorfields and Chair of Retinal Studies at University College London. The procedure was successfully performed without any complications. ACT and Moorfields Eye Hospital recently received clearance from the Data and Safety Monitoring Board (DSMB) to treat the final two patients in the first cohort of this clinical trial.
"We are very pleased to continue our forward momentum with both our U.S. trials and our European trial," commented Gary Rabin, chairman and CEO. "It was less than a month ago that we received DSMB approval to treat the second and third patients in our E.U. trial, and it is very gratifying to have already completed dosing of the second. It is a pleasure to be working with Professor Bainbridge and the rest of his team at Moorfields Eye Hospital, and we continue to be encouraged by the steady progress of the trial thus far."
The Phase 1/2 trial is designed to determine the safety and tolerability of hESC-derived RPE cells following sub-retinal transplantation in patients with SMD at 12 months, the study's primary endpoint. It will involve a total of 12 patients, with cohorts of three patients each in an ascending dosage format. It is similar in design to the U.S. trial for SMD that was initiated in July 2011.
The European Medicines Agency's (EMA) Committee for Orphan Medicinal Products (COMP) has officially designated ACT's human embryonic stem cell (hESC)-derived retinal pigment epithelial (RPE) cells as an orphan medicinal product for the treatment of Stargardt's Macular Dystrophy (SMD).
More information on the status of the company's clinical trials will be posted today on Mr. Rabin's Chairman's blog.
About Stargardt's Disease Stargardt's disease or Stargardt's Macular Dystrophy is a genetic disease that causes progressive vision loss, usually starting in children between 10 to 20 years of age. Eventually, blindness results from photoreceptor loss associated with degeneration in the pigmented layer of the retina, called the retinal pigment epithelium, which is the site of damage that the company believes the hESC-derived RPE may be able to target for repair after administration.
About Advanced Cell Technology, Inc. Advanced Cell Technology, Inc. is a biotechnology company applying cellular technology in the field of regenerative medicine. For more information, visit http://www.advancedcell.com .
Need more good news, the SEC lawsuit settled, the reverse split done, partner, and good results from trial.
Good luck in this rigged casino,
Subscribe to:
Posts (Atom)